Dr. Jagabandhu Das - CML - Chronic myeloid leukemia
''Received Ph. D. degree in chemistry from the University of New Brunswick, Fredericton, NB, Canada in 1978. Joined Squibb Institute for Medical Research as a research investigator in 1982 after postdoctoral research in the laboratory of Prof. E. J. Corey at Harvard University. At present is a research fellow in Drug Discovery Chemistry at Bristol-Myers Squibb Pharmaceutical Research Institute. Extensive research experience in organic synthesis , and medicinal chemistry with concentration in immunology, oncology, and cardiovascular diseases. Holder of 57 issued U. S. patents and 45 publications. Listed as whos who in American Men and Women of Science, and Marquis whos who in America. Co-discoverer of the multi-kinase inhibitor dasatinib (SPRYCEL)which is currently approved for the treatment of chronic myeloid leukemia (CML), and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) in patients with resistance to or intolerant of prior therapy including imatinib.'' |
ARTICLES
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
August 2013, Journal of Cancer Research and Clinical Oncology
How Jagabandhu Das made dasatinib possible
January 16, 2012, C&En
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
August 2013, Journal of Cancer Research and Clinical Oncology
How Jagabandhu Das made dasatinib possible
January 16, 2012, C&En
Modes of access to the website
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website.
(No registration required - Anonymous access)
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website.
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
